The number of diagnosed prevalent drug-treated mHSPC cases in the 8MM will rise from 196,867 in 2025 to 244,101 by 2033.

The potential of moving the combination to the earlier MIBC setting significantly increases the Padcev market.

A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.

The AAM’s Giuseppe Randazzo warns that the generics business could become unsustainable in the future if the market dynamics ...

France-based Adcytherix has completed a Series A funding round, raising €105m ($122m) earmarked for expediting the ADC ...

EMD Serono has partnered the Trump administration to expand access to the company’s in vitro fertilisation (IVF) therapies.

ZETA’s digital solutions enable pharmaceutical and biotech companies to accelerate innovation, streamline operations, and ...

AstraZeneca has unveiled a newly expanded manufacturing facility in Texas to the tune of $445m, as the drugmaker aims to meet ...

Novo Nordisk will now run a Phase III trial for Omeros' former lead asset, zaltenibart in rare blood disorder, PNH.

With a legacy rooted in global scientific excellence, Sweden is quietly building one of Europe’s most dynamic biotech ...

Tubulis has completed a Series C, securing €308m ($361m) to be directed towards advancing clinical development of its ADC ...

A consortium led by Nordic Capital and Permira has raised its bid, though certain shareholder stances remain firm.